Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.
By M. McQueen, S. Hawken, Xingyu Wang, S. Ôunpuu, Allan Sniderman, J. Probstfield, K. Steyn, J. Sanderson, M. Hasani, E. Volkova and 2 more. The Lancet, 2008
764 citations recorded by the source corpus.
Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/b57fdb86ae02c8b4df1ee99f7a1f25c60add3126
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “Non-HDL-C predicts CVD risk even better than LDL-C.351 LDL-C limits may be transferred to non-HDL-C limits by adding 0.8 mmol/L (30 mg/dL).”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “Non-HDL-C predicts CVD risk even better than LDL-C.351 LDL-C limits may be transferred to non-HDL-C limits by adding 0.8 mmol/L (30 mg/dL).”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “Based on the available evidence, it appears that apoB is a similar risk marker to LDL-C [356].”
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “Based on the available evidence, it appears that apoB is a similar risk marker to LDL cholesterol and a better index of the adequacy of LDL-lowering therapy.(476) Also, there appears to be less laboratory error in the determination of apoB than LDL cholesterol, particularly in patients with hypertri”